Design Therapeutics, Inc.
DSGNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 2, 2026 | Wells Fargo | $26.00(+112%) | $12.24 | TheFly | |
| May 4, 2026 | Oppenheimer | $21.00(+58%) | $13.30 | TheFly | |
| Apr 29, 2026 | Piper Sandler | $20.00(+31%) | $15.24 | TheFly | |
| Jan 7, 2026 | Oppenheimer | $18.00(+104%) | $8.82 | TheFly | |
| Dec 3, 2025 | Craig-Hallum | Adam Vogel | $15.00(+68%) | $8.94 | TheFly |
| Dec 3, 2025 | Leerink Partners | Joseph Schwartz | $14.00(+57%) | $8.94 | TheFly |
| May 7, 2024 | Piper Sandler | Yasmeen Rahimi | $12.00(+229%) | $3.65 | StreetInsider |
| Aug 15, 2023 | RBC Capital | Leonid Timashev | $7.00(+223%) | $2.17 | Benzinga |
| Dec 7, 2022 | Piper Sandler | Yasmeen Rahimi | $42.00(+231%) | $12.69 | TheFly |
| May 2, 2022 | RBC Capital | $30.00(+151%) | $11.94 | Benzinga | |
| Jan 19, 2022 | Goldman Sachs | Madhu Kumar | $10.00(-28%) | $13.98 | Pulse 2.0 |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| RBC Capital | maintain | Outperform | Nov 5, 2026 |
| Oppenheimer | maintain | Outperform | May 4, 2026 |
| RBC Capital | maintain | Outperform | Mar 10, 2026 |
| Leerink Partners | upgrade | Market Perform →Outperform | Dec 3, 2025 |
| RBC Capital | upgrade | Sector Perform →Outperform | Nov 20, 2025 |
| RBC Capital | maintain | Sector Perform | Nov 6, 2025 |
| RBC Capital | maintain | Sector Perform | Aug 6, 2024 |
| Piper Sandler | upgrade | Neutral →Overweight | May 7, 2024 |
| Wedbush | maintain | Neutral | Mar 20, 2024 |
| RBC Capital | maintain | Sector Perform | Mar 20, 2024 |
| RBC Capital | maintain | Sector Perform | Nov 14, 2023 |
| Wedbush | downgrade | Outperform →Neutral | Aug 15, 2023 |
| SVB Leerink | downgrade | Outperform →Market Perform | Aug 15, 2023 |
| RBC Capital | downgrade | Outperform →Sector Perform | Aug 15, 2023 |
| Wedbush | maintain | Outperform | May 10, 2023 |
| RBC Capital | maintain | Outperform | May 10, 2023 |
| Goldman Sachs | upgrade | Sell →Neutral | May 4, 2023 |
| RBC Capital | maintain | Outperform | Mar 15, 2023 |
| SVB Leerink | maintain | Outperform | Dec 9, 2022 |
| RBC Capital | maintain | Outperform | Dec 8, 2022 |
| Wedbush | maintain | Outperform | Aug 9, 2022 |
| Wedbush | maintain | Outperform | Jun 10, 2022 |
| Goldman Sachs | maintain | Sell | May 24, 2022 |
| SVB Leerink | maintain | Outperform | May 10, 2022 |
| RBC Capital | maintain | Outperform | May 2, 2022 |
Earnings History
Next report: Mar 8, 2027 · EPS est. $-0.38| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-0.32 | $-0.34 | — | — |
| Aug 3, 2026 | $-0.32 | $-0.34 | — | — |
| Apr 28, 2026 | $-0.29 | $-0.36 | — | — |
| Mar 9, 2026 | $-0.27 | $-0.38 | — | — |
| Nov 5, 2025 | $-0.30 | $-0.34 | — | — |
| Aug 7, 2025 | $-0.34 | $-0.32 | — | — |
| May 7, 2025 | $-0.31 | $-0.28 | — | — |
| Mar 10, 2025 | $-0.24 | $-0.28 | — | — |
News
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 Cash and securities of $208.6 million at quarter-end provide strong financial runway CARLSBAD, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2026 financial results and highlighted business updates and upcoming milestone…
Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the root cause of Friedreich Ataxia [FA]. The company's 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements, but confirmation awaits 12-week results in Q1 2027. Upcoming catalysts include a registrational update in Q4 2026 for DT-216P2 FA and early-stage readouts for DM1 and FECD programs in 2027.
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation
Bank of New York Mellon Corp acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ: DSGN) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 92,069 shares of the company's stock, valued at approximately $1,332,000. Bank of New York
CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m.
BlackRock Inc. acquired a new position in Design Therapeutics, Inc. (NASDAQ: DSGN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,660,024 shares of the company's stock, valued at approximately $38,491,000. BlackRock Inc. owned about 4.25% of Design
An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.